AzTrials
AzTrials

Platinum-resistant Recurrent Ovarian Cancer (PROC)Phase 2NCT07314619

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

A Phase 2 study testing Sacituzumab Tirumotecan Combined with Bevacizumab in people with Platinum-resistant Recurrent Ovarian Cancer (PROC), run by The First Affiliated Hospital of Zhengzhou University at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

As one of the gynecological malignancies with the highest incidence and mortality rates worldwide, ovarian cancer treatment faces the significant challenge of platinum-resistant recurrence. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Sacituzumab Tirumotecan Combined with Bevacizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
30 Dec 2025to 30 Dec 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1.Sign a written informed consent form before undergoing any trial-related procedures;
  • 2.Female, aged ≥ 18 years;
  • 3.Histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; with platinum resistance (recurrence within 6 months after the last platinum dose);
  • 4.Enrolled subjects must have received at least one but no more than three prior systemic treatment regimens, and the prior regimens may include bevacizumab and/or poly(ADP-ribose) polymerase inhibitors (PARPi);
  • 5.For subjects with brain metastases, only those with asymptomatic or symptomatically stable brain metastases are eligible for enrollment;
  • 6.ECOG performance status score of 0-1;
Show all 19Show fewer
  • 7.Expected survival time > 6 months;
  • 8.Adequate organ function, with subjects required to meet the following laboratory parameters:
  • Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹/L without the use of granulocyte colony-stimulating factor (G-CSF) within the past 14 days;
  • Platelet count ≥ 100×10⁹/L without blood transfusion within the past 14 days;
  • Hemoglobin > 9 g/dL without blood transfusion or use of erythropoietin within the past 14 days;
  • Total bilirubin ≤ 1.5×Upper Limit of Normal (ULN);
  • Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5×ULN;
  • Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL/min;
  • Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5×ULN;
  • Normal thyroid function, defined as Thyroid-Stimulating Hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects may still be enrolled if their total triiodothyronine (T3) (or free triiodothyronine, FT3) and free thyroxine (FT4) are within the normal range;
  • Cardiac enzyme profile within the normal range (subjects with isolated laboratory abnormalities deemed clinically insignificant by the investigator may also be enrolled);
  • 9.For women of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days before the first administration of the study drug (Cycle 1, Day 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women who are not of childbearing potential are defined as those who are postmenopausal for at least 1 year, or have undergone surgical sterilization or hysterectomy;
  • 10.For female subjects with fertility potential, they must agree to use effective medical contraceptive measures from the time of signing the informed consent form until 6 months after the last dose of the study drug.

Who cannot join

  • 1.Diagnosis of other malignant diseases within 5 years before the first dose (excluding radically treated basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and/or carcinoma in situ with radical resection);
  • 2.Known presence of active bleeding signs in lesions as shown by endoscopy;
  • 3.Currently participating in therapeutic intervention clinical research, or having received other study drugs or treatment with study devices within 4 weeks before the first dose;
  • 4.Previous receipt of the following therapies: ADC drugs targeting FR-α, or TROP2-targeted treatments (such as any drug therapy containing topoisomerase I targeting agents, including antibody-drug conjugate (ADC) therapy);
  • 5.Systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural effusion) within 2 weeks before the first dose;
  • 6.Occurrence of active autoimmune diseases requiring systemic treatment (e.g., disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years before the first dose. Replacement therapies (e.g., thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment;
Show all 32Show fewer
  • 7.Receipt of systemic glucocorticoid therapy (excluding nasal spray, inhaled, or other forms of local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose of the study; Note: Use of physiological doses of glucocorticoids (≤ 10 mg/day of prednisone or equivalent) is permitted;
  • 8.Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
  • 9.Known hypersensitivity to the drugs used in this study;
  • 10.Failure to fully recover from toxicity and/or complications caused by any intervention (i.e., ≤ Grade 1 or return to baseline, excluding fatigue or alopecia) before the start of treatment;
  • 11.Known history of human immunodeficiency virus (HIV) infection (i.e., positive HIV 1/2 antibodies);
  • 12.Untreated active hepatitis B (defined as positive HBsAg with HBV-DNA copy number exceeding the upper limit of normal of the laboratory in the research center); Note: Hepatitis B subjects meeting the following criteria may also be enrolled: a) HBV viral load < 1000 copies/ml (200 IU/ml) before the first dose, and subjects should receive anti-HBV treatment throughout the study chemotherapy period to prevent viral reactivation; b) For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and negative HBV viral load, prophylactic anti-HBV treatment is not required, but close monitoring for viral reactivation is necessary;
  • 13.Subjects with active HCV infection (positive HCV antibodies and HCV-RNA level above the lower limit of detection);
  • 14.Receipt of live vaccines within 30 days before the first dose (Cycle 1, Day 1); Note: Receipt of inactivated viral vaccines for seasonal influenza via injection within 30 days before the first dose is permitted; however, intranasal attenuated live influenza vaccines are not allowed;
  • 15.Pregnant or lactating women;
  • 16.Presence of any severe or uncontrollable systemic diseases, such as:
  • Significant and severely symptomatic, uncontrollable abnormalities in resting electrocardiogram (ECG) in terms of rhythm, conduction, or morphology, such as complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmia, or atrial fibrillation;
  • Unstable angina pectoris, congestive heart failure, or chronic heart failure with New York Heart Association (NYHA) classification ≥ Grade 2;
  • Any arterial thrombosis, embolism, or ischemia (e.g., myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack) occurring within 6 months before enrollment;
  • Poorly controlled blood pressure (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg);
  • History of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose, or current clinically active interstitial lung disease;
  • Active pulmonary tuberculosis;
  • Presence of active or uncontrolled infection requiring systemic treatment;
  • Presence of clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction;
  • Liver diseases such as liver cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  • Poorly controlled diabetes mellitus (fasting blood glucose (FBG) > 10 mmol/L);
  • Urinalysis indicating urine protein ≥ ++, and confirmed 24-hour urine protein quantification > 1.0 g;
  • Patients with mental disorders who are unable to cooperate with treatment;
  • 17.Need for use of strong inhibitors or inducers of cytochrome P450 3A4 enzyme (CYP3A4) within 2 weeks before the first dose and during the study period (use of strong CYP3A4 inhibitors or inducers is not permitted in this study; all subjects must avoid concurrent use of any drugs, herbal supplements, and/or ingestion of such foods known to induce CYP3A4 as much as possible);
  • 18.Documented history of severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or corneal disease that impairs delayed corneal wound healing;
  • 19.History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid treatment, current presence of ILD or non-infectious pneumonia, or suspected ILD or non-infectious pneumonia at screening that cannot be excluded by imaging examination;
  • 20.Evidence of medical history, disease, treatment, or abnormal laboratory test results that may interfere with study results, prevent the subject from completing the study, or other circumstances deemed unsuitable for enrollment by the investigator (including other potential risks considered by the investigator that make the subject unfit for participation in this study).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Xie Ya contact

Professor

wangxinxin058@126.com

China1 site

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000

Other trials in China

About this study

As one of the gynecological malignancies with the highest incidence and mortality rates worldwide, ovarian cancer treatment faces the significant challenge of platinum-resistant recurrence. Patients with platinum-resistant recurrent ovarian cancer (PROC) have an extremely poor prognosis, and the survival benefits of traditional chemotherapy and bevacizumab combination therapy are limited (median progression-free survival [mPFS] is approximately 2-5 months, and 5-year survival rate is 30%-40%). In recent years, the antibody-drug conjugate (ADC) Sacituzumab tirumotecan has shown breakthrough potential. A phase Ⅱ study presented at the 2024 European Society for Medical Oncology (ESMO) Congress demonstrated that for patients with advanced platinum-resistant ovarian cancer (87.5% of whom had platinum resistance) treated with this drug as monotherapy, the objective response rate (ORR) reached 40%, median progression-free survival (mPFS) was 6.0 months, and disease control rate (DCR) was 75%. Furthermore, the ORR increased to 61.5% in patients with high Trop2 expression, and the safety profile was manageable.Based on the preclinical model evidence suggesting that anti-angiogenic drugs can enhance the intratumoral penetration of ADCs, the current study further explores the synergistic effect of Sacituzumab tirumotecan combined with bevacizumab. It aims to improve therapeutic efficacy by optimizing tumor microcirculation and analyze the molecular mechanisms using technologies such as organoids and single-cell sequencing, thereby providing a new strategy to overcome the bottleneck of platinum resistance.

Being tested
Sacituzumab Tirumotecan Combined with Bevacizumab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sacituzumab Tirumotecan Combined with BevacizumabDrug

    Sacituzumab Tirumotecan is administered at a dose of 4 mg/kg via intravenous infusion, with a treatment cycle of every 2 weeks, and is given once on Day 1 of each cycle.

    Bevacizumab is administered at a dose of 7.5~15 mg/kg via intravenous infusion, once every 3 weeks.

    Treatment is continued until disease progression or the occurrence of intolerable toxicity.

Study groups in NCT07314619
Study groupRoleWhat they receive
Sacituzumab tirumotecan combined with bevacizumabExperimentalNot described
Receives: Drug: Sacituzumab Tirumotecan Combined with Bevacizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ORR

    ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST 1.1 assessed by the investigators.

    Measured: Up to 24 months

Secondary outcomes (3)

  1. PFS

    PFS is defined as the time from the first administration to the first documented progressive disease (PD) per RECIST 1.1 by investigators or death due to any cause, whichever occurs first.

    Measured: Up to 24 months

  2. OS

    OS is defined as the time from the first receipt of treatment under the study protocol to the death of the subject due to any reason.

    Measured: Up to 24 months

  3. Adverse Events (AEs)

    The number of participants experiencing an AE will be assessed

    Measured: Up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jan 2026
  2. Study start30 Dec 2025 (estimated)
  3. Primary completion30 Dec 2027 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07314619
Sponsor's protocol ID
SKB264-NSIP-032
Status last verified
Dec 2025
First submitted
18 Dec 2025
Last updated
2 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Sacituzumab Tirumotecan Combined with Bevacizumab in people with Platinum-resistant Recurrent Ovarian Cancer (PROC), run by The First Affiliated Hospital of Zhengzhou University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xie Ya (Professor, wangxinxin058@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ORR (time frame: Up to 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07314619.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in